MedTrace Logo

MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism

NCT02102646 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2015-10-28

No results posted yet for this study

Summary

The purpose of this study is to investigate if androgen deprivation therapy in men with prostate cancer increases hepatic fat content and changes visceral/subcutaneous fat distribution.

Conditions

Interventions

DRUG

Triptorelin

Androgen deprivation therapy by Pamorelin 22,5mg/24 weeks administered intramuscularly.

PROCEDURE

Orchiectomy

Androgen deprivation therapy by bilateral subcapsular orchiectomy

Sponsors & Collaborators

  • Herlev Hospital

    lead OTHER

Principal Investigators

  • Peter B Østergren, MD · Department of Urology, Herlev Hospital, Denmark

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02102646 on ClinicalTrials.gov